Cas:216854-55-6 S-(1,2-diformylpyrazolidin-4-yl) ethanethioate manufacturer & supplier

Chemical Name:S-(1,2-diformylpyrazolidin-4-yl) ethanethioate

CAS.NO:216854-55-6

Synonyms:4-(acetylthio)-1,2-diformyl pyrazolidine

Molecular Formula:C₇H₁₀N₂O₃S

Molecular Weight:202.23100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:82.99000

Exact Mass:202.04100

LogP:0.62770

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(acetylthio)-1,2-diformyl pyrazolidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(acetylthio)-1,2-diformyl pyrazolidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(acetylthio)-1,2-diformyl pyrazolidine Use and application,4-(acetylthio)-1,2-diformyl pyrazolidine technical grade,usp/ep/jp grade.

Related News: Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. S-(1,2-diformylpyrazolidin-4-yl) ethanethioate manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. S-(1,2-diformylpyrazolidin-4-yl) ethanethioate supplier Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. S-(1,2-diformylpyrazolidin-4-yl) ethanethioate vendor The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. S-(1,2-diformylpyrazolidin-4-yl) ethanethioate factory Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.